Congress demands full disclosure of secret drug pricing deals with manufacturers
H.R. 9699 — Drug Deal Disclosure Act · Filed by Judy Chu (D-CA) · 24 cosponsors · Introduced Jul 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Health and Human Services to publicly release all documents, contracts, and communications related to drug pricing agreements struck between the federal government and pharmaceutical manufacturers since January 20, 2025—including deals involving most-favored-nation pricing, direct-to-consumer sales, import duty exemptions, and special regulatory treatment. The bill names 17 specific manufacturers with whom such agreements were announced, mandates disclosure within 30 days, and requires Congress and independent auditors to analyze the economic and budgetary effects of these deals on drug prices and federal programs.
Why we flagged it
The bill's core mechanism is compulsory public disclosure of previously confidential government-manufacturer agreements, paired with independent congressional and GAO analysis of their fiscal and competitive effects. It is a transparency and accountability tool, not a substantive pricing policy.
What the text implies
- Disclosure of 'proprietary pricing information' may be heavily redacted under permitted withholdings, potentially limiting the transparency benefit if manufacturers claim broad confidentiality protections under foreign law or settlement agreements.
- The bill does not mandate renegotiation or cancellation of existing agreements—it only requires disclosure. Citizens may learn what deals were struck but have no direct remedy if terms are unfavorable.
The full analysis lists 4 implications of this text.
Who it affects
Ordinary citizens gain transparency into how federal drug pricing negotiations affect their out-of-pocket costs and insurance premiums, and Congress gains independent analysis of whether these deals deliver promised savings. The bill restricts government secrecy and manufacturer confidentiality claims—both forms of power asymmetry that typically harm public accountability—without blocking any citizen rights or remedies.